Obermatt

Astellas Pharma

TYO:4503 · JP3942400007
PharmaceuticalsX-Large

360

100
EV / EBIT83
Price / Owner Earnings95
Owner Earnings Yield96
Dividend Yield99
Price/Sales64
EV / Gross Profit97
Price/Book71
Return on Capital61
Cash Return on Capital90
Return on Equity75
EBIT Margin34
Gross Profitability86
Cash Conversion73
Accruals92
Owner Earnings Margin79
Sales growth15
Profit Growth35
Long-Term EPS Growth82
Owner Earnings Growth85
Reinvestment34
Price momentum97
Debt load48
Refinancing20
Debt Payback40
Liquidity81
Analyst ratings1
Opinion Changes28
Price Target Upside56
Market mood61
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Astellas Pharma generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryJapan
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeTSE
Founded1939
Employees5,806
ISINJP3942400007
Last UpdateApr 2, 2026
Themes
HematologyDiabetesImmunologyOphthalmologyUrologyDermatologyOncologyBiotechnologyHealth CareMedical

Description

Astellas Pharma Inc. (Astellas), a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. Astellas not only focuses on traditional prescription medications (Rx) but also explores…

Analysis

Hidden champion

Astellas Pharma Inc. is what we call a hidden champion: a strong business that the market is not pricing as one.

The price is attractive. You pay 8.4× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -6% yearly growth; analysts expect 17%. The price, in other words, assumes less than the experts do.

The trajectory is solid and the balance sheet is sturdy. The company scores 20/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
66
2023202420252026

All-time high

93

Feb 2026

All-time low

12

Jan 2024

Average rank

62

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
64
74
59
50
Price/Earnings
74
42
58
80
Price/Book
71
41
45
53
Dividend Yield
99
96
93
82
Value (overall)
98
74
50
57

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Astellas Pharma with its peers
Yuyu Pharma
KSC:000220
81
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Yungjin Pharm
KSC:003520
34
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
WuXi Biologics (Cayman)
HKG:2269
87
CountryHong Kong SAR China
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Whanin Pharm
KSC:016580
99
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sino Biopharmaceutical
HKG:1177
55
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Samsung Pharm
KSC:001360
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →